Analyst Ratings For Bellicum Pharmaceuticals (NASDAQ:BLCM)
Today, Citigroup raised its price target on Bellicum Pharmaceuticals (NASDAQ:BLCM) to $27.00 per share.
Some recent analyst ratings include
- 1/31/2018-Cantor Fitzgerald Reiterated Rating of Overweight .
- 1/31/2018-Wells Fargo & Co was Downgraded by analysts at Wells Fargo & Co from a “Outperform ” rating to a ” Market Perform” rating. They now have a $6.00 price target on the stock.
- 12/12/2017-Raymond James Financial Reiterated Rating of Buy.
- 9/14/2017-Jefferies Group Reiterated Rating of Buy.
Recent Insider Trading Activity For Bellicum Pharmaceuticals (NASDAQ:BLCM)
Bellicum Pharmaceuticals (NASDAQ:BLCM) has insider ownership of 18.77% and institutional ownership of 55.21%.
- On 1/19/2018 Bros. Advisors Lp Baker, Major Shareholder, sold 880,735 with an average share price of $8.20 per share and the total transaction amounting to $7,222,027.00.
- On 1/17/2018 Bros. Advisors Lp Baker, Major Shareholder, sold 260,600 with an average share price of $8.63 per share and the total transaction amounting to $2,248,978.00.
- On 1/9/2018 Alan K Smith, EVP, sold 487 with an average share price of $9.40 per share and the total transaction amounting to $4,577.80.
- On 12/11/2017 Alan A Musso, CFO, sold 17,117 with an average share price of $9.33 per share and the total transaction amounting to $159,701.61.
- On 11/27/2017 Alan A Musso, CFO, sold 6,206 with an average share price of $9.89 per share and the total transaction amounting to $61,377.34.
- On 7/24/2017 Alan K. Smith, EVP, sold 437 with an average share price of $11.85 per share and the total transaction amounting to $5,178.45.
- On 7/13/2017 Ken Moseley, VP, sold 13,823 with an average share price of $12.26 per share and the total transaction amounting to $169,469.98.
Recent Trading Activity for Bellicum Pharmaceuticals (NASDAQ:BLCM)
Shares of Bellicum Pharmaceuticals closed the previous trading session at 6.36 up +0.39 6.45% with 6.53000020980835 shares trading hands.